Cadrenal Therapeutics Names John Sharp Interim CFO; Recaps $3M Private Placement
CVKD sits 28% above its 52-week low of $2.55.
Summary
Cadrenal Therapeutics has appointed John Sharp as interim Chief Financial Officer, replacing Quang Pham. This leadership change comes as the company also recaps a $3.0 million private placement, which was initially announced on July 1st via news and an 8-K filing. The financing is critical for the company, which reported a going concern warning and a cash runway only into October 2026 in its May 7th 10-Q. The appointment of an interim CFO is a key development for a small biotech navigating significant financial and operational needs.
At the time of this announcement, CVKD was trading at $3.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.3M. The 52-week trading range was $2.55 to $14.64. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.